"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 3 | 4 |
| 2000 | 3 | 1 | 4 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 3 | 6 |
| 2003 | 0 | 3 | 3 |
| 2004 | 3 | 4 | 7 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 0 | 1 |
| 2007 | 7 | 4 | 11 |
| 2008 | 5 | 1 | 6 |
| 2009 | 3 | 3 | 6 |
| 2010 | 2 | 8 | 10 |
| 2011 | 8 | 1 | 9 |
| 2012 | 7 | 4 | 11 |
| 2013 | 9 | 8 | 17 |
| 2014 | 5 | 2 | 7 |
| 2015 | 8 | 4 | 12 |
| 2016 | 6 | 4 | 10 |
| 2017 | 12 | 5 | 17 |
| 2018 | 11 | 5 | 16 |
| 2019 | 4 | 3 | 7 |
| 2020 | 11 | 3 | 14 |
| 2021 | 11 | 2 | 13 |
| 2022 | 6 | 1 | 7 |
| 2023 | 9 | 1 | 10 |
| 2024 | 7 | 5 | 12 |
| 2025 | 10 | 2 | 12 |
| 2026 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Novel application of dried blood spot tenofovir diphosphate to predict viral suppression in postpartum women with HIV in Malawi. AIDS. 2026 May 01; 40(5):589-599.
-
Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIV. J Control Release. 2026 02 10; 390:114559.
-
Low-level viraemia as a risk factor for virologic failure in children and adolescents living with HIV on antiretroviral therapy in Tanzania: a multicentre, retrospective cohort study. J Int AIDS Soc. 2025 May; 28(5):e26474.
-
Attitudes and Barriers Toward Antiretroviral Therapeutic Drug Monitoring Among Infectious Disease Providers. Medicina (Kaunas). 2025 Mar 20; 61(3).
-
Assessing BE FASTER, a Community of Practice Among Ryan White Part A Clinics in Houston, to Increase Rapid Initiation of Antiretroviral Therapy: A Qualitative, Longitudinal Study. Perm J. 2025 12 15; 29(4):2-9.
-
Predicting mortality within 1 year of ART initiation in children and adolescents living with HIV in sub-Saharan Africa: a retrospective observational cohort study. Lancet Glob Health. 2024 06; 12(6):e929-e937.
-
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. Lancet HIV. 2024 04; 11(4):e211-e221.
-
Intervention Fidelity to VITAL Start (Video Intervention to Inspire Treatment Adherence for Life) in a Randomized Controlled Trial Among Women Living With HIV in Malawi. Health Promot Pract. 2025 01; 26(1):131-141.
-
Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis. Clin Infect Dis. 2023 01 06; 76(1):10-17.
-
Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children. Clin Infect Dis. 2022 08 25; 75(2):347-355.